Cellebrite DI (NASDAQ:CLBT) Insider Holly Windham Sells 3,049 Shares of Company Stock

Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) insider Holly Windham sold 3,049 shares of the business’s stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $10.65, for a total value of $32,471.85. Following the sale, the insider owned 92,279 shares of the company’s stock, valued at approximately $982,771.35. This represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Cellebrite DI Stock Up 1.4%

Shares of NASDAQ:CLBT opened at $11.32 on Friday. The firm’s 50 day moving average price is $11.57 and its 200-day moving average price is $13.14. Cellebrite DI Ltd. has a twelve month low of $9.58 and a twelve month high of $19.39. The stock has a market capitalization of $2.82 billion, a PE ratio of 33.82, a price-to-earnings-growth ratio of 1.41 and a beta of 1.06.

Institutional Trading of Cellebrite DI

Several institutional investors and hedge funds have recently added to or reduced their stakes in CLBT. Nine Ten Capital Management LLC boosted its stake in Cellebrite DI by 19.8% in the 2nd quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company’s stock worth $60,251,000 after purchasing an additional 682,933 shares during the period. Wellington Management Group LLP grew its holdings in Cellebrite DI by 93.7% during the 2nd quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock valued at $44,529,000 after buying an additional 1,475,579 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Cellebrite DI by 14.7% during the first quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock valued at $39,420,000 after buying an additional 365,700 shares during the last quarter. Portolan Capital Management LLC raised its position in shares of Cellebrite DI by 1.8% during the third quarter. Portolan Capital Management LLC now owns 1,967,445 shares of the company’s stock valued at $22,153,000 after buying an additional 34,931 shares during the last quarter. Finally, Weiss Asset Management LP raised its position in shares of Cellebrite DI by 3,485.3% during the first quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock valued at $26,180,000 after buying an additional 1,846,851 shares during the last quarter. Institutional investors own 45.88% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings raised shares of Cellebrite DI from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, November 13th. DA Davidson reaffirmed a “buy” rating and issued a $15.00 target price on shares of Cellebrite DI in a report on Tuesday, September 15th. Needham & Company LLC lifted their target price on Cellebrite DI from $12.50 to $14.00 and gave the company a “buy” rating in a research report on Thursday, November 12th. JPMorgan Chase & Co. cut their price target on Cellebrite DI from $16.00 to $15.00 and set an “overweight” rating for the company in a report on Friday, November 13th. Finally, Lake Street Capital decreased their price objective on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Cellebrite DI currently has a consensus rating of “Moderate Buy” and an average price target of $14.75.

Read Our Latest Report on Cellebrite DI

About Cellebrite DI

(Get Free Report)

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.

Featured Articles

Insider Buying and Selling by Quarter for Cellebrite DI (NASDAQ:CLBT)

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.